Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose derived mesenchymal stromal cells (AD-MSCs) are multipotent stem/stromal cells isolated from human adipose (fat) tissue. They are capable of differentiating into various cell types including osteoblasts (bone), chondrocytes (cartilage), myocytes (muscle), and adipocytes (fat). AD-MSCs exhibit strong immunomodulatory and anti-inflammatory properties by secreting a range of cytokines and growth factors such as VEGF, FGF, HGF, NGF, IL-1, IL-6 and IL-10. These properties make them attractive for regenerative medicine applications including wound healing; orthopedic conditions like bone defects; cardiovascular diseases; autoimmune disorders; and inflammatory skin diseases such as psoriasis and atopic dermatitis. Compared to bone marrow-derived MSCs they are easier to obtain in higher yields with less invasive procedures[2][3][6]. AD-MSCs have low immunogenicity due to reduced MHC class I expression and can suppress lymphocyte proliferation[2][3]. Their clinical use is under investigation in multiple phase 1/2 trials for diverse indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adipose derived mesenchymal stromal cells.